Delcath Systems, Inc. (NASDAQ:DCTH) Receives $22.50 Consensus PT from Analysts

Delcath Systems, Inc. (NASDAQ:DCTH) has received an average recommendation of “Hold” from the seven analysts that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $22.50.

Several research analysts have recently issued reports on the stock. BTIG Research reduced their target price on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Weiss Ratings upgraded shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Wall Street Zen downgraded shares of Delcath Systems from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Evercore set a $27.00 price target on shares of Delcath Systems in a research report on Thursday, February 26th. Finally, Zacks Research downgraded shares of Delcath Systems from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th.

Institutional Trading of Delcath Systems

A number of hedge funds and other institutional investors have recently made changes to their positions in DCTH. California State Teachers Retirement System acquired a new position in Delcath Systems during the second quarter worth $26,000. Russell Investments Group Ltd. bought a new position in Delcath Systems during the third quarter worth $29,000. Tower Research Capital LLC TRC bought a new position in Delcath Systems during the second quarter worth $40,000. Legal & General Group Plc bought a new position in Delcath Systems during the second quarter worth $46,000. Finally, The Manufacturers Life Insurance Company bought a new position in Delcath Systems during the second quarter worth $151,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Stock Down 0.4%

Shares of NASDAQ:DCTH opened at $11.72 on Wednesday. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $15.57. The company’s 50-day moving average price is $10.82 and its two-hundred day moving average price is $10.13. The firm has a market cap of $404.57 million, a P/E ratio of 1,172.00 and a beta of 0.54.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07. The firm had revenue of $24.99 million for the quarter, compared to analyst estimates of $23.51 million. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. As a group, equities analysts predict that Delcath Systems will post -0.88 earnings per share for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.